Key result
Fibrinogen β-455 G/A and prothrombin 20210 G/A polymorphisms showed no significant difference in genotype distribution and allele frequency between CHD patients and healthy controls.
Why the study?
Are FGB-455 G/A and PT 20210 G/A polymorphisms associated with an increased risk of coronary heart disease in Egyptian patients?
Case-Control (n=60)
No
Are FGB-455 G/A and PT 20210 G/A polymorphisms associated with an increased risk of coronary heart disease in Egyptian patients?
Answers are grounded in this paper and cite their sources.
FGB-455 G/A and PT 20210 G/A polymorphisms do not appear to be significant genetic risk factors for coronary heart disease in this Egyptian cohort.
Objective Coronary heart disease (CHD) is a complex disease with both environmental and genetic determinants. The aim of this study was to assess the presence of fibrinogen β-chain (FGB)-455 G/A and prothrombin (PT) 20210 G/A polymorphisms in CHD Egyptian patients and to correlate the co-existence of both polymorphisms with the clinical and laboratory data of the patients. Methods Thirty adult patients with angiographically documented CHD from the National Heart Institute, scheduled for elective coronary artery bypass graft surgery, were included in this study and compared with 30 age-matched and sex-matched healthy individuals. DNA was extracted from the peripheral blood and identification of FGB-455 and PT 20210 genotypes was carried out. Results The fibrinogen-455 locus showed three polymorphisms (GG, GA, and AA), whereas the PT 20210 locus showed two polymorphisms (GG and GA). The genotype distribution and frequency of the mutated alleles in both polymorphisms showed no significant difference between patient and control groups (P>0.05). Conclusion Accordingly, none of the polymorphisms can be considered as a risk factor for CHD in the studied Egyptian patients, and the co-existence of FGB-455 G/A and PT 20210 G/A cannot be implicated in the occurrence of CHD and, moreover, was not reported in the studied Egyptian participants.
No takes yet. Share an insight, caveat, or question.
Shaker et al. (2011) conducted a case-control in Coronary heart disease (n=60). Fibrinogen β-455 G/A and prothrombin 20210 G/A polymorphisms vs. Healthy individuals was evaluated on Genotype distribution and frequency of the mutated alleles (p=>0.05). Fibrinogen β-455 G/A and prothrombin 20210 G/A polymorphisms showed no significant difference in genotype distribution and allele frequency between CHD patients and healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: